Myomo, Inc. (MYO)
| Market Cap | 209.11M |
| Revenue (ttm) | 25.24M |
| Net Income (ttm) | -8.38M |
| Shares Out | 33.24M |
| EPS (ttm) | -0.28 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,698 |
| Open | 6.39 |
| Previous Close | 6.31 |
| Day's Range | 6.22 - 6.44 |
| 52-Week Range | 2.51 - 7.17 |
| Beta | 1.68 |
| Analysts | Strong Buy |
| Price Target | 8.25 (+31.16%) |
| Earnings Date | Mar 6, 2025 |
About MYO
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living. It also provides the MyoPro 2, including control technology, configuration software and user interface, and pop-out battery for extended use of... [Read more]
Financial Performance
In 2023, Myomo's revenue was $19.24 million, an increase of 23.70% compared to the previous year's $15.56 million. Losses were -$8.15 million, -24.00% less than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for MYO stock is "Strong Buy." The 12-month stock price forecast is $8.25, which is an increase of 31.16% from the latest price.
News
Myomo, Inc. Prices $15.0 Million Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper l...
Myomo, Inc. Announces Proposed Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper l...
Myomo, Inc. (MYO) Q3 2024 Earnings Call Transcript
Myomo, Inc. (MYO) Q3 2024 Earnings Call Transcript
Myomo Reports Record Third Quarter Financial and Operating Results
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...
CMS Decision And O&P Network Build Out Make Myomo A Buy
Myomo's business model is now sustainable due to CMS reclassifying MyoPro, leading to lump sum payments and consistent insurance coverage. Medicare Part B coverage has significantly improved Myomo's o...
Myomo Announces First Private Payer Contracts for MyoPro In-network Coverage
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...
Myomo to Report Third Quarter Financial Results on November 6, 2024
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...
Myomo to Participate in the 2024 Maxim Healthcare Virtual Summit
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...
Myomo, Inc. Announces the Launch of Myomo Academy at AOPA National Assembly
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...
Myomo to Participate in Two Investor Conferences in September
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...
Myomo, Inc. (MYO) Q2 2024 Earnings Call Transcript
Myomo, Inc. (NYSE:MYO) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Kim Golodetz - LHA Investor Relations Paul Gudonis - Chief Executive Officer Dave Henry - Chief ...
Myomo Reports Second Quarter 2024 Financial Results
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...
Myomo to Report Second Quarter Financial Results on August 6, 2024
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...
Myomo Reports Preliminary Second Quarter 2024 Revenues and Operating Metrics
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...
Myomo to Present at the Sidoti Virtual Investor Conference on June 12-13, 2024
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...
Myomo, Inc. (MYO) Q1 2024 Earnings Call Transcript
Myomo, Inc. (NYSE:MYO) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Kim Golodetz - LHA Investor Relations Paul Gudonis - Chief Executive Officer Dave Henry - Chief Fin...
Myomo Reports First Quarter 2024 Financial Results
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...
Myomo Announces First Lump Sum Reimbursements for MyoPros Delivered to Medicare Part B Beneficiaries Under New CMS Fees
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...
Myomo to Report First Quarter Financial Results on May 8, 2024
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...
Myomo Appoints Heather Getz to its Board of Directors
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...
Myomo's Revolutionary MyoPro Brace: A Buy In Neurological Mobility Aid
Myomo offers revolutionary MyoPro braces that enhance mobility for upper limb disabilities due to various neurological conditions. The company is experiencing a record number of orders, leading to sus...
Myomo, Inc.: In Motion To Accelerating Revenue Growth
Medicare decision created a multi-decade revenue growth opportunity. Soft Q1 guidance due to non-recurring timing issues. 2024 guidance gives only partial-year credit to reimbursement change.
Myomo, Inc. (MYO) Q4 2023 Earnings Call Transcript
Myomo, Inc. (NYSE:MYO) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET
Myomo Reports Fourth Quarter and Full Year 2023 Financial Results
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...
CMS Posts Final Medicare DMEPOS Fee Schedule Rate for the MyoPro®
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...